Intravaginal @entity3402 treatment for @entity6981 : effects on XXXX and low birth weight.

@entity1 @entity3152 @entity6981 @entity3402
OBJECTIVE: Our goal was to evaluate whether treatment of @entity6981 during pregnancy with 2% @entity3402 vaginal cream reduces the incidence of either @entity3152 or low birth weight or of both. STUDY DESIGN: A multicenter, double-blind, randomized, placebo-controlled trial in Indonesia compared a 2% @entity3402 vaginal cream with a placebo cream. @entity1 seeking prenatal care at 14 to 26 weeks of gestational age who had @entity6981 (Gram stain score > 6 and pH of vaginal fluid > 4.5) were invited to participate. Of the 745 @entity1 enrolled, 681 (91.4%) @entity1 were followed up through delivery. RESULTS: @entity3402 vaginal cream was an effective treatment for @entity6981 . Two weeks after completion of the treatment, 85.5% of the @entity1 were cured. The rate of @entity3152 (< 37 weeks) was 15.0% for @entity3402 @entity1 and 13.5% for placebo @entity1 (odds ratio 1.1, 95% confidence interval 0.7 to 1.7). The rate of low birth weight was 9.0% for @entity3402 @entity1 and 6.8% for placebo @entity1 (odds ratio 1.3, 95% confidence interval 0.8 to 2.4). CONCLUSIONS: Treatment of @entity6981 with @entity3402 vaginal cream did not reduce @entity3152 or low birth weight. Although @entity3402 vaginal cream is an effective treatment for @entity6981 , intravaginal treatment would not be effective against @entity6981 harbored in the upper genital tract. Systemic treatment may be required to eradicate upper tract infection to reduce @entity3152 .
